Data Release Ignites Buzz: Social media chatter has intensified around Viking Therapeutics following a recent positive data release on its obesity treatment candidate. Analysts and traders highlighted substantial weight loss results and promising maintenance dosing options that could enhance patient convenience. The stock experienced a sharp intraday surge as participants noted the durability of effects in clinical observations.
Phase 3 Focus Emerges: Discussions emphasize the upcoming Phase 3 trials as a key milestone, with observers pointing to the company's strong cash position and low debt levels. Many expressed interest in the potential for dosing flexibility compared to existing therapies. Overall market attention has shifted toward execution risks and commercialization pathways in the competitive obesity space.
Note: This discussion summary was generated from an AI condensation of post data.
Viking Therapeutics Insider Trading Activity
Viking Therapeutics insiders have traded $VKTX stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $VKTX stock by insiders over the last 6 months:
- BRIAN LIAN (President & CEO) sold 148,517 shares for an estimated $4,947,888
- GREG ZANTE (Chief Financial Officer) sold 21,217 shares for an estimated $710,141
- MARIANNA MANCINI (Chief Operating Officer) sold 18,217 shares for an estimated $609,635
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Viking Therapeutics Hedge Fund Activity
We have seen 206 institutional investors add shares of Viking Therapeutics stock to their portfolio, and 231 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RAYMOND JAMES FINANCIAL INC removed 1,280,743 shares (-61.7%) from their portfolio in Q2 2026, for an estimated $49,961,784
- JPMORGAN CHASE & CO added 915,185 shares (+inf%) to their portfolio in Q2 2026, for an estimated $35,701,366
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 730,690 shares (+inf%) to their portfolio in Q2 2026, for an estimated $28,504,216
- BLACKROCK, INC. removed 690,641 shares (-10.0%) from their portfolio in Q2 2026, for an estimated $26,941,905
- JUMP FINANCIAL, LLC added 579,882 shares (+inf%) to their portfolio in Q2 2026, for an estimated $22,621,196
- TWO SIGMA INVESTMENTS, LP removed 494,728 shares (-11.2%) from their portfolio in Q2 2026, for an estimated $19,299,339
- AMERIPRISE FINANCIAL INC added 477,338 shares (+28.4%) to their portfolio in Q2 2026, for an estimated $18,620,955
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Viking Therapeutics Price Targets
Multiple analysts have issued price targets for $VKTX recently. We have seen 3 analysts offer price targets for $VKTX in the last 6 months, with a median target of $100.0.
Here are some recent targets:
- Daniel Brims from Lake Street set a target price of $89.0 on 05/28/2026
- Jeet Mukherjee from BTIG set a target price of $125.0 on 05/01/2026
- Steve Seedhouse from Cantor Fitzgerald set a target price of $100.0 on 04/30/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
